Topical Sirolimus in Cutaneous Lymphatic Malformations
NCT03972592
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
55
Enrollment
OTHER
Sponsor class
Conditions
Vascular Malformations
Lymphatic Malformation
Interventions
DRUG:
Topical 0.1% Sirolimus
DRUG:
Topical Vehicle
Sponsor
University Hospital, Tours
Collaborators
[object Object]